TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05184413

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unimodal treatment
Description: An unimodal telerehabilitation intervention will be performed through Whatsapp video calls. The treatment will include only a therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
Study: NCT05190640

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: De-Stress Gummies
Description: one gummy a day for De-Stress Gummies and one gummy a day for Sleep Gummies
Study: NCT04656782

Intervention type: OTHER
Intervention: Imaging survey
Description: Participation as expert panelist in the imaging survey.

Intervention type: OTHER
Intervention: Facilitation
Description: Moderation and evaluation of the expert panel's answers. Adoption and moderation of further survey rounds.
Study: NCT06387563

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal activation using pressure biofeedback
Description: PBF assisted abdominal muscle activation training (30 min, 3x /week /4 weeks) Progressive Muscle Relaxation for 5 min Pressure biofeedback assisted abdominal muscle activation training. Frequency: 25 min; 10 sec hold, 15 sec relax, 10 reps Progression criteria in training: Maintaining 3 - 5 mmHg pressure on PBF dial while performing abdominal muscle activation.~Exercises for Group For biofeedback assisted abdominal muscle activation training these exercises will be performed:~1. Supine abdominal muscle activation (45° Hip knee flexion)~2. Both hip and knee 90° flexion~3. One side hip and knee 90° flexion with other fully extended~4. One side hip and knee 90° flexion with other fully extended + heel 12 cm raised~5. Both legs fully extended with heel 12 cm raised~6. Partial curl ups~7. Prone lying abdominal muscle activation~8. Prone leg raises~9. Prone upper back extension simple~10. Prone reciprocal UE/LE exercises

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal activation using SEMG biofeedback
Description: SEMG-BF assisted abdominal muscle activation training (30 min, 3x/ week/ 4 weeks) Progressive Muscle Relaxation for 5 min Surface EMG-BF assisted abdominal muscle activation training. Frequency: 25 min; 10 sec hold, 15 sec relax, 10 reps Maintaining minimal volumetric contraction of abdominal muscle activation (as per person) on SEMG device with abdominal muscle activation for set frequency~Exercises for Group B For biofeedback assisted abdominal muscle activation training these exercises will be performed:~1. Supine abdominal muscle activation (45° Hip knee flexion)~2. Both hip and knee 90° flexion~3. One side hip and knee 90° flexion with other fully extended~4. One side hip and knee 90° flexion with other fully extended + heel 12 cm raised~5. Both legs fully extended with heel 12 cm raised~6. Partial curl ups~7. Prone lying abdominal muscle activation~8. Prone leg raises~9. Prone upper back extension simple~10. Prone reciprocal UE/LE exercises
Study: NCT06238323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LAFIYA
Description: LAFIYA will be a modified version of the Many Men Many Voices (3MV) targeted at addressing reducing stigma and increasing HIV self-testing uptake among young sexual minority men. LAFIYA will be developed into a comprehensive intervention manual for a large-scale trial using the ADAPTT-IT framework.
Study: NCT04880551

Intervention type: RADIATION
Intervention: Fluoroscopy
Description: In this study the patient will be exposed to radiation during the fluoroscopy for lungs. There is a small chance of alopecia. There is a rare chance that the patients skin may turn red or be damaged.
Study: NCT05930093

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching LivPhcD cap.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2 cap.LivPhcD/per day
Description: 2 caps. LivPhcD cap. after meal, once a day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4 cap.LivPhcD/per day
Description: 4 caps. LivPhcD cap. after meal, BID

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 6 cap.LivPhcD/per day
Description: 6 caps. LivPhcD cap. after meal, TID
Study: NCT06537804

Intervention type: RADIATION
Group type: OTHER
Intervention: Screening by low-dose CT scan
Description: Screening for lung cancer by low-dose CT scan
Study: NCT06387251

Intervention type: OTHER
Group type: OTHER
Intervention: 30 day wellness program
Description: 30 days and will evaluate the effects of sponsor-designed 30-day wellness program consisting of 3 supplement and functional food products, recommended diet, physical activity, hydration and mindfulness activities.

Intervention type: OTHER
Group type: OTHER
Intervention: 30 day wellness program
Description: 30 days and will evaluate the effects of sponsor-designed 30-day wellness program consisting of 3 supplement and functional food products, recommended diet, physical activity, hydration and mindfulness activities.
Study: NCT06047769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Board Games
Description: Participants will receive cognitive training in board games including Ludo, Chutes \& Ladder and Chess with both single and multiplayer modes. After 1 week of training, participants will receive intervention of 1 hour per day, three days a week for 8 weeks completing a total of 1440 minutes. With this technique, we will target the cognitive process of information processing, speed and executive function of the patient.
Study: NCT04641273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Tablet, intake orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Tablet, intake orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Tablet, intake orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Tablet, intake orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BAY1817080
Description: Tablet, intake orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BAY1817080
Description: Tablet, intake orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for BAY1817080
Description: Tablet, intake orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Pregabalin
Description: Capsule, intake orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Pregabalin
Description: Capsule, intake orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Pregabalin
Description: Capsule, intake orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Pregabalin
Description: Capsule, intake orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Capsule, intake orally. Starting dose 75 mg BID first week, increase to 150 mg BID in second week.
Study: NCT06286956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment of rectal lesions with UNI-VEC
Description: Polyp resections
Study: NCT05561387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05445037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemodynamic continuous monitoring
Description: Continuous monitoring will be done with clearsight continuously assessing blood pressure, cardiac output and heart rate; NIRS electrode to assess cerebral O2 saturation, peripheral O2 saturation, BIS value and axillary temperature.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Monitoring
Description: Standard monitoring will be done with non-invasive blood pressure, heart rate, NIRS electrode to access cerebral O2 saturation, peripheral O2 saturation, axillary temperature, BIS value. In addition, patients will use Clearsight, but the device will be blind to the anesthesiologist. Pressure monitoring will be every 5 min.
Study: NCT05719844

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Description: List of neuropsychological tests:~* Matrix reasoning~* D2-R~* Coding~* Symbol search~* Digit span~* Alertness (computerized TAP battery)~* Divided Attention (computerized TAP battery)~* Go / No go (computerized TAP battery)~* Incompatibility (computerized TAP battery)~* Working memory (computerized TAP battery)~* 16-item Free and Cued Recall or Stories subtest of the Children Memory Scale (CMS) for children only (\< 17 years old)~* complex figure of the memory efficiency battery 144 or Word pairs of the Children Memory Scale for children only (\< 17 years old)
Study: NCT04957914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC
Study: NCT05309707

Intervention type: DEVICE
Intervention: Endovascular exclusion
Description: Endovascular exclusion by branch stent graft systems (Nexus stent-graft system®, Relay Branch® or Zenith arch branch graft®), with proximal landing at zone 0.
Study: NCT06156579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 20 mg/m\^2, i.v., once daily, 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax, 400 mg, p.o., once daily, 28 days
Study: NCT05070689

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACCSS
Description: A. Chohan Continuous Squeezing Suture (ACCSS)
Study: NCT05886673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental cream
Description: experimental cream

Intervention type: OTHER
Group type: OTHER
Intervention: standard of care
Description: standard of care
Study: NCT05268965

Intervention type: BEHAVIORAL
Intervention: Experimental: group comparison
Description: * Standardized psychiatric interview (Mini International Neuropsychiatric Interview MINI)~* State-Trait-Anxiety Inventory (Spielberger, 1993)~* Beck Depression Inventory (BDI-II, 1998)~* Cognitive Emotional Regulation Questionnaire (Jermann \& al., 2006) Participant installation and testing: 2 stages (forecasting on a computer, and exposure in virtual reality)~Task / affective forecasting:~* Step 1: forecasting about one's own emotional responses regarding pleasant, neutral and unpleasant scenarios~* Step 2: experience of the same scenarios in virtual reality

Intervention type: BEHAVIORAL
Intervention: Experimental: group comparison
Description: * Standardized psychiatric interview (Mini International Neuropsychiatric Interview MINI)~* State-Trait-Anxiety Inventory (Spielberger, 1993)~* Beck Depression Inventory (BDI-II, 1998)~* Cognitive Emotional Regulation Questionnaire (Jermann \& al., 2006) Participant installation and testing: 2 stages (forecasting on a computer, and exposure in virtual reality)~Task / affective forecasting:~* Step 1: forecasting about one's own emotional responses regarding pleasant, neutral and unpleasant scenarios~* Step 2: experience of the same scenarios in virtual reality
Study: NCT05205772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: Transcranial magnetic stimulation (or TMS) is a non-invasive form of brain stimulation in which a magnetic pulse is applied directly to the scalp. This device is FDA approved for treatment of depression and other neuropsychiatric disorders, and is regularly used in neurologic and psychiatric research.~iTBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz very quickly). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatments lasts approximately 3 minutes.
Study: NCT05268965

Intervention type: BEHAVIORAL
Intervention: Experimental: group comparison
Description: * Standardized psychiatric interview (Mini International Neuropsychiatric Interview MINI)~* State-Trait-Anxiety Inventory (Spielberger, 1993)~* Beck Depression Inventory (BDI-II, 1998)~* Cognitive Emotional Regulation Questionnaire (Jermann \& al., 2006) Participant installation and testing: 2 stages (forecasting on a computer, and exposure in virtual reality)~Task / affective forecasting:~* Step 1: forecasting about one's own emotional responses regarding pleasant, neutral and unpleasant scenarios~* Step 2: experience of the same scenarios in virtual reality
Study: NCT06114810

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: polio vaccines: nOPV2, bOPV, IPV
Description: Co-administration of nOPV2 with bOPV along with IPV with different sequential or combination schedules.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: polio vaccines: nOPV2, bOPV, IPV
Description: Co-administration of nOPV2 with bOPV along with IPV with different sequential or combination schedules.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: polio vaccines: nOPV2, bOPV, IPV
Description: Co-administration of nOPV2 with bOPV along with IPV with different sequential or combination schedules.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: polio vaccines: nOPV2, bOPV, IPV
Description: Co-administration of nOPV2 with bOPV along with IPV with different sequential or combination schedules.
Study: NCT05723861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR
Description: We will use the Pico Headset, a three-dimensional Gear with a connected tablet, and will be positioned on the head with elastic straps. Patients will be instructed about the VR device before their procedure and virtual experiences will initiate just before colonoscope insertion and continuously delivered throughout the procedure for max of 20 minutes. Patients will experience max of 20 minutes of VR and if colonoscopy lasts longer than 20 min, the remaining time of colonoscopy will be performed without using VR. The visualized content of VR will be chosen by the participants among three available contents including beach, nature, or mountain with relaxing music. Participants could opt out and/or request standard medications for pain at any time before or during the procedure.
Study: NCT06119074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gifted Savings
Description: Gifted Savings assets will be in the form of cash, Bitcoin, and/or stock. Participants will receive identical asset portfolios. The asset mix will be determined by Gifted Savings. Participants will not have any control over the assets they receive, nor the proportion of each in their account. After registration on the Gifted Savings website, participants can immediately withdraw $100 USD if they choose. Then, for each of the first two years, participants may withdraw up to $500 USD for an emergency (self-attested) if the value of the account is 50% or more of its value 30 days prior and the account has sufficient funds to fulfill the request. Two years post-enrollment, participants may withdraw the entire value of their GS account or continue holding the assets in their GS account (in perpetuity or until the GS non-profit ceases to exist). GS funds are unconditional; there are no restrictions or limitations on how the money can be spent.
Study: NCT06216626

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: myota's prebiotic fibre blend
Description: Each 10g daily serve of supplement contains the following fibres:~* Fructooligosaccharides~* Inulin~* Resistant dextrin~* Resistant maltodextrin~* Partially hydrolysed guar gum~* Guar gum

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: myota's prebiotic fibre blend
Description: Each 10g daily serve of supplement contains the following fibres:~* Fructooligosaccharides~* Inulin~* Resistant dextrin~* Resistant maltodextrin~* Partially hydrolysed guar gum~* Guar gum
Study: NCT06326281

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unilateral external oblique intercostal plane block group
Description: USG guided external oblique intercostal plane block will perform unilateral with Bupivacaine 25 patient included and patients were observed for pain for 24 hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unilateral oblique subcostal transversus abdomınıs plane block group
Description: USG guided oblique subcostal transversus abdomınıs plane block block will perform unilateral with Bupivacaine. 25 patient included and patients were observed for pain for 24 hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic infiltration group
Description: Bupivacaine infiltration will be performed to trocar insertion sites. 25 patient included and patients were observed for pain for 24 hours

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: All patients were followed using a standardized postoperative analgesia protocol which includes tramadol patient controlled analgesia. Tramadol at a concentration of 5 mg/mL is included in our patient controlled analgesia protocol (total volume 100 mL.) patient controlled analgesias were set to no basal infusion and 10 mg bolus doses with a 20 min lock time 25 patient included and patients were observed for pain for 24 hours
Study: NCT05434533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)
Description: IV 1gm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)
Description: IV 1gm
Study: NCT05106023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: SHR-1701 combined with temozolomide
Study: NCT05743985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cannabigerol
Description: Hemp-derived full spectrum cannabigerol oil carried in an organic coconut (MCT) oil within hydroxypropyl methylcellulose capsules.
Study: NCT05745857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erbitux
Description: Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erbitux
Description: Orally administered

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy
Description: Fluorescent endoscope fiber and spectroscopy probe will be inserted through the working channel of the normal clinical therapeutic endoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy
Description: Fluorescent endoscope fiber and spectroscopy probe will be inserted through the working channel of the normal clinical therapeutic endoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy
Description: Fluorescent endoscope fiber and spectroscopy probe will be inserted through the working channel of the normal clinical therapeutic endoscope
Study: NCT05642572

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Given IV
Study: NCT04177511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: Transcutaneous Auricular Vagus Nerve Stimulation has an eartip connected to an external stimulator. The device used in this study is the TENS Eco Plus commercialized by Schwa Medico and European Compliance (CE) marked.~The electrode is positioned in the cymba concha of the left ear.